Proximity to oil refineries and risk of bladder cancer: A population-based analysis.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 4538-4538
Author(s):  
Tamer Dafashy ◽  
Daniel Phillips ◽  
Mohamed Danny Ray-Zack ◽  
Preston Kerr ◽  
Yong Shan ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Incidence ◽  
Census Data ◽  
The United States ◽  
Population Based ◽  
Incidence Rates ◽  
Oil Refinery ◽  
Oil Refineries ◽  
Background Exposure ◽  
Cancer Incidence Rates

4538 Background: Exposure to aromatic amines is a risk factor for bladder cancer. Incidence rates according to proximity to oil refineries are largely unknown. We sought to determine proximity of oil refineries and bladder cancer incidence in the State of Texas which is home to the largest number of oil refineries in the United States. Methods: We used the Texas Cancer Registry database to identify patients diagnosed with bladder cancer from January 1, 2001 to December 31, 2014. The U.S. census data from 2010 was used to ascertain overall population size, age and sex distributions. Heat maps of the 28 active oil refineries in Texas were developed. Incidence of bladder cancer were compared according to proximity ( < 10 vs. ≥ 10 miles) to an oil refinery. Risk ratios were adjusted using a Poisson regression model. Results: A total of 45,517 incident bladder cancer cases were identified of which 5,501 cases were within 10 miles of an oil refinery. In adjusted analyses, bladder cancer risk was significantly greater among males vs. females (Relative Risk (RR) 3.41, 95% Confidence Interval (CI), 3.33-3.50), and greater among people living within 10 miles from an oil refinery than those living outside a 10-mile radius from an oil refinery (RR 1.19, 95% CI, 1.08-1.31). Conclusions: People living within 10 miles from oil refineries were at greater risk for bladder cancer. Further research into exposure to oil refineries and bladder cancer incidence is warranted.

Incidence of Invasive Breast Cancer by Hormone Receptor Status From 1992 to 1998

2003 ◽  
Vol 21 (1) ◽  
pp. 28-34 ◽  
Author(s):  
Christopher I. Li ◽  
Janet R. Daling ◽  
Kathleen E. Malone
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Cancer Incidence ◽  
Hormone Receptor ◽  
Breast Cancer Incidence ◽  
The United States ◽  
Incidence Rates ◽  
Hormone Receptor Status ◽  
Receptor Status ◽  
Cancer Incidence Rates

Purpose: Between 1987 and 1998, breast cancer incidence rates rose 0.5%/yr in the United States. A question of potential etiologic and clinical importance is whether the hormone receptor status of breast tumors is also changing over time. This is because hormone receptor status may reflect different etiologic pathways and is useful in predicting response to adjuvant therapy and prognosis. Methods: Age-adjusted, age-specific breast cancer incidence rates by estrogen receptor (ER) and progesterone receptor (PR) status from 1992 to 1998 were obtained and compared from 11 population-based cancer registries in the United States that participate in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program. Results: From 1992 to1998, the overall proportion of breast cancers that were ER-positive and PR-positive increased from 75.4% to 77.5% (P = .0002) and from 65.0% to 67.7% (P < .0001), respectively, continuing trends observed before 1992. These increases were limited to women 40 to 69 years of age. The proportions of ER-positive/PR-positive tumors increased from 56.7% to 62.3% (P = .0010) among 40- to 49-year-olds, from 58.0% to 63.2% (P = .0002) among 50- to 59-year-olds, and from 63.2% to 67.9% (P = .0020) among 60- to 69-year-olds. Conclusion: From 1992 to 1998, the proportion of tumors that are hormone receptor–positive rose as the proportion of hormone receptor–negative tumors declined. Because the incidence rates of hormone receptor–negative tumors remained fairly constant over these years, the overall rise in breast cancer incidence rates in the United States seems to be primarily a result of the increase in the incidence of hormone receptor–positive tumors. Hormonal factors may account for this trend.

Abstract A113: Regional variations in esophageal cancer incidence rates by census region in the United States, 1999-2008

2012 ◽  
Vol 5 (11 Supplement) ◽  
pp. A113-A113
Author(s):  
Jennifer Drahos ◽  
Manxia Wu ◽  
William F. Anderson ◽  
Katrina F. Trivers ◽  
Jessica King ◽  
...  
Keyword(s):  
United States ◽  
Esophageal Cancer ◽  
Cancer Incidence ◽  
The United States ◽  
Incidence Rates ◽  
Regional Variations ◽  
Cancer Incidence Rates

scholarly journals Machine Learning Methods to Identify Missed Cases of Bladder Cancer in Population-Based Registries

2021 ◽  
pp. 641-653
Author(s):  
Anne-Michelle Noone ◽  
Clara J. K. Lam ◽  
Angela B. Smith ◽  
Matthew E. Nielsen ◽  
Eric Boyd ◽  
...  
Keyword(s):  
United States ◽  
Machine Learning ◽  
Bladder Cancer ◽  
Cancer Incidence ◽  
Cancer Registries ◽  
The United States ◽  
Population Based ◽  
Learning Methods ◽  
Machine Learning Methods ◽  
Classification And Regression

PURPOSE Population-based cancer incidence rates of bladder cancer may be underestimated. Accurate estimates are needed for understanding the burden of bladder cancer in the United States. We developed and evaluated the feasibility of a machine learning–based classifier to identify bladder cancer cases missed by cancer registries, and estimated the rate of bladder cancer cases potentially missed. METHODS Data were from population-based cohort of 37,940 bladder cancer cases 65 years of age and older in the SEER cancer registries linked with Medicare claims (2007-2013). Cases with other urologic cancers, abdominal cancers, and unrelated cancers were included as control groups. A cohort of cancer-free controls was also selected using the Medicare 5% random sample. We used five supervised machine learning methods: classification and regression trees, random forest, logic regression, support vector machines, and logistic regression, for predicting bladder cancer. RESULTS Registry linkages yielded 37,940 bladder cancer cases and 766,303 cancer-free controls. Using health insurance claims, classification and regression trees distinguished bladder cancer cases from noncancer controls with very high accuracy (95%). Bacille Calmette-Guerin, cystectomy, and mitomycin were the most important predictors for identifying bladder cancer. From 2007 to 2013, we estimated that up to 3,300 bladder cancer cases in the United States may have been missed by the SEER registries. This would result in an average of 3.5% increase in the reported incidence rate. CONCLUSION SEER cancer registries may potentially miss bladder cancer cases during routine reporting. These missed cases can be identified leveraging Medicare claims and data analytics, leading to more accurate estimates of bladder cancer incidence.

scholarly journals Cervical Cancer Incidence Rates in Texas Counties 1995–2015

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Nicholas Salas
Keyword(s):  
United States ◽  
Cervical Cancer ◽  
Spatial Distribution ◽  
Cancer Incidence ◽  
The United States ◽  
Incidence Rates ◽  
The Political ◽  
Cervical Cancer Incidence ◽  
Race Ethnicity ◽  
Cancer Incidence Rates

As of 2014, Texas has the 6th highest incidence rate and the 5th highest mortality rate of cervical cancer in the nation. In addition, Texas ranks 3rd to last in the United States in human papilloma (HPV) vaccinations, which helps prevent one of the leading causes of cervical cancer. Cervical cancer incidence rates in Texas remain high, despite it becoming one the most successfully preventable treatable cancers in the United States due to a combination of screenings and HPV vaccinations. Furthermore, spatial distribution of cervical cancer is unknown among Texas counties. This study will follow the political ecology model to elaborate on the political, historical, social, and economic factors that may explain why HPV vaccinations are low and the incidence rate remains high despite the interventions available to people in Texas. This study will examine the geography of cervical cancer in Texas counties from 1995 - 2015 as well as its relationship with religious adherence, socioeconomic status, race/ethnicity, and uninsured rates. I will use a bivariate correlation to relate these factors with cancer incidence rates and ArcMap to create maps to illustrate the spatial distribution of these diseases. The data will be obtained from the Texas Cancer Registry, Texas County Health Rankings 2018, and the Association of Religion Data (CDC) Archives (ARDA). I expect that cervical cancer rates will decline after the introduction of the HPV vaccine in 2007, but areas with higher religious adherence will have higher rates of cervical cancer. In addition, I expect that uninsured rates, race/ethnicity, and socioeconomic factors could possibly impact cervical cancer incidence rates.

Predicting future cancer incidence by age and gender.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 1559-1559 ◽  
Author(s):  
Wesley B. Garner ◽  
Benjamin D. Smith ◽  
Jacob Ezra Shabason ◽  
Grant Richard Williams ◽  
Michelle Y. Martin ◽  
...  
Keyword(s):  
Older Adults ◽  
Cancer Incidence ◽  
The United States ◽  
Incidence Rates ◽  
Population Projections ◽  
Age And Gender ◽  
Total Cancer ◽  
And Gender ◽  
The Impact ◽  
Cancer Incidence Rates

1559 Background: Cancer remains a substantial and unique burden on society. While the impact of changing demographics on cancer incidence has previously been characterized (Smith et al, JCO, 2009), this has not been done with updated population data. Our objective was to update projections on the number of new cancer diagnoses in the United States by age and gender through 2040. Methods: Population-based cancer incidence data were obtained using SEER 18 delay-adjusted data. Population estimates were made by age, race, and gender using the 2010 US Census data population projections to calculate future cancer incidence rates. Trends in age- adjusted incidence rates for 23 cancer types were calculated as previously described (Edwards et al, Cancer, 2014). Results: From 2020 to 2040 the projected total cancer incidence will increase by almost 30% from 1.86 million to 2.4 million. This increase is due to the projected increase in population growth, particularly in older individuals. The population of older adults will represent a growing proportion of total cancer diagnoses. Specifically, patients ≥65 years old will make up 69% of all new cancer diagnoses, while 13% of new diagnoses will be in patients ≥85 years old by 2040 (see Table). Cancer diagnoses in females are projected to rise 27%, while male cancer diagnoses are projected to increase by 32% from 2020 to 2040. The incidence rates for lung, colorectal, and prostate cancer are expected to decline, while those for thyroid, liver, melanoma and myeloma are expected to increase. Conclusions: The landscape of cancer care will continue to change over the next several decades. The burden of disease will remain substantial and will continue to disproportionately affect older adults. The growing proportion of older cancer patients and changes in site-specific cancer incidence rates remain of particular interest. These projections should help guide future health policy and research priorities. [Table: see text]

scholarly journals Projected Cancer Incidence Rates and Burden of Incident Cancer Cases in HIV-Infected Adults in the United States Through 2030

2018 ◽  
Vol 168 (12) ◽  
pp. 866 ◽  
Author(s):  
Meredith S. Shiels ◽  
Jessica Y. Islam ◽  
Philip S. Rosenberg ◽  
H. Irene Hall ◽  
Evin Jacobson ◽  
...  
Keyword(s):  
United States ◽  
Cancer Incidence ◽  
The United States ◽  
Incidence Rates ◽  
Incident Cancer ◽  
Cancer Incidence Rates
Sign in / Sign up

Export Citation Format

Share Document